Cempra to Present at Two Upcoming Scientific Conferences
April 17 2015 - 7:30AM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in
the treatment of bacterial infectious diseases, today announced it
will be participating in the 25th European Congress of Clinical
Microbiology (ECCMID), in Copenhagen, Denmark, April 25-28 and the
2015 Pediatric Academic Societies (PAS) Annual Meeting in San
Diego, April 25-28. Additional abstracts of solithromycin study
results are being submitted for presentation at appropriate medical
meetings.
Presentations at ECCMID:
- Results of a Global Phase 3 Trial Comparing Oral Solithromycin
versus Oral Moxifloxacin for Treatment of Community Acquired
Bacterial Pneumonia (CABP) in Adults – LBOS Late breaker: results
from latest clinical trial, April 28, oral presentation by David
Oldach at 11:54 a.m. CET in Hall E. An abstract for the late
breaker presentation is available on the ECCMID meeting
website.
- Solithromycin, a 4th Generation Macrolide and the 1st
Fluoroketolide, Does Not Prolong the QTc Interval: Results of a
Definitive QT Study – E-poster, April 25 (all day).
- In vitro susceptibility of S. pneumoniae to solithromycin (SOL)
in Belgian and German collections with an elevated percentage of
isolates resistant to macrolides and fluoroquinolones – E-poster,
April 25 (all day).
- Efficacy of Solithromycin against Enterococcus faecalis in a
Neutropenic Mouse Thigh Abscess Model – E-poster, April 25 (all
day).
- Activity of Fusidic acid (FUS) alone or in combination with
Daptomycin (DAP), Vancomycin (VAN), or Linezolid (LDZ) in an in
vitro model of Staphylococcus aureus Biofilm – E-Poster, April 25
(all day).
- Rifampin (RIF) significantly reduces plasma concentrations of
fusidic acid (FA) when used in combination for treatment of
prosthetic joint infection (PJI) – Poster, Poster Area, April 28 at
12:30 p.m. CET. An abstract is available using the link
Rifampin.
Presentation at PAS:
- Pharmacokinetics and Safety of Solithromycin in Adolescents
with Suspected or Confirmed Bacterial Infection – Poster, Exhibit
Hall EFG, April 25 at 1:00 p.m. PDT. This work was funded by BARDA
(Biomedical Advanced Research and Development Authority).
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused
on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead
product candidates are currently in advanced clinical development.
Solithromycin (CEM-101) is in Phase 3 clinical development for
community acquired bacterial pneumonia (CABP) and is licensed to
strategic commercial partner Toyama Chemical Co., Ltd., a
subsidiary of FUJIFILM Holdings Corporation, for certain exclusive
rights in Japan. Solithromycin has also entered a Phase 3 clinical
trial for uncomplicated bacterial urethritis caused by Neisseria
gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second
product candidate, which is being developed for chronic oral
treatment of refractory infections in bones and joints. Both
products seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the
community. The company has also synthesized novel macrolides for
non-antibiotic uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Cempra
was founded in 2006 and is headquartered in Chapel Hill, N.C. For
additional information about Cempra please visit
www.cempra.com.
CONTACT: Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media Contacts:
Russo Partners, LLC
Robert E. Flamm, Ph.D.
(212) 845-4226
robert.flamm@russopartnersllc.com
Lena Evans
(212) 845-4262
lena.evans@russopartnersllc.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2024 to May 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From May 2023 to May 2024